The news: Clarity Pharmaceuticals shares tumbled after it announced a new treatment in its pipeline for breast cancer. The numbers: The clinical-stage radiopharmaceutical company’s shares dropped 5.36 ...

Enhertu (fam-trastuzumab deruxtecan-nxki) has received FDA approval for HR-positive, HER2-low, HER2-ultralow metastatic breast cancer.

Although common, the cause of these hernias is unknown, and the only treatment ... Cancer Vaccine Shows Promise for Patients With Stage III and IV Kidney Cancer Feb. 5, 2025 — Researchers report ...

In patients with high-risk HER2-positive breast cancer, post-surgery, or adjuvant, treatment with trastuzumab emtansine (T-DM1) reduced the long-term risk of death or invasive disease by 46% and ...

This study presents a useful finding that targeting amino acid metabolism can overcome Trastuzumab resistance in HER2+ breast cancer. The evidence supporting the claims of the authors is solid and the ...

Given the evolving role of trastuzumab deruxtecan (Enhertu) in the treatment of breast cancer, especially those who are HER2 positive, staying vigilant in looking for signs of adverse events (AEs) is ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The addition of trastuzumab and pertuzumab to chemotherapy was associated with increased toxicity in patients with ...

New approval brings the medicine to an earlier treatment setting and a broader patient population.